|
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, discovery of more potent PME-1 inhibitors may be beneficial for the treatment of endometrial cancer.
|
27048286 |
2016 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Here, we show that covalent PME-1 inhibitors decrease cell proliferation and invasive growth in vitro but have no effect in vivo at the concentrations tested; however, depletion of PME-1 with shRNA in an endometrial cancer xenograft model significantly reduced tumor growth.
|
27048286 |
2016 |
|
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, discovery of more potent PME-1 inhibitors may be beneficial for the treatment of endometrial cancer.
|
27048286 |
2016 |
|
Malignant neoplasm of endometrium
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings identify PME-1 as a modifier of malignant development and suggest its candidacy as a diagnostic marker and as a therapeutic target in endometrial cancer.
|
24928782 |
2014 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In clinical specimens of endometrial adenocarcinoma, PME-1 levels were increased and we found that PME-1 overexpression was sufficient to drive tumor growth in a xenograft model of the disease.
|
24928782 |
2014 |
|
Endometrial Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings identify PME-1 as a modifier of malignant development and suggest its candidacy as a diagnostic marker and as a therapeutic target in endometrial cancer.
|
24928782 |
2014 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Nevertheless, PP2A inactivation in the latter cancer types is common via other mechanisms, in particular by increased expression of Cancerous Inhibitor of PP2A (CIP2A) and PP2A Methylesterase-1 (PME-1) proteins.
|
31214504 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Out of the examined PP2A inhibitors (CIP2A, SET, PME1, ARPP19 and TIPRL), expression of ARPP19 mRNA was found to be independent of the current AML risk classification.
|
31717978 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Nevertheless, PP2A inactivation in the latter cancer types is common via other mechanisms, in particular by increased expression of Cancerous Inhibitor of PP2A (CIP2A) and PP2A Methylesterase-1 (PME-1) proteins.
|
31214504 |
2019 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
|
29281045 |
2018 |
|
Progressive supranuclear palsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
|
29281045 |
2018 |
|
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.
|
29281045 |
2018 |
|
Adenocarcinoma of rectum
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Analysis of PPME-1 mRNA expression from TCGA dataset of colon and rectal adenocarcinoma (COADREAD) patient cohort confirmed high PPME1 expression as an independent protective factor predicting favorable overall survival (OS) (P = 0.005, n = 396) compared to patients with low PPME1 expression.
|
26377365 |
2015 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing an array comparative genomic hybridization analysis to detect copy number changes, we have been the first to identify PPME1 gene amplification in 3.8% (5/131) of Chinese gastric cancer (GC) samples and 3.1% (4/124) of Chinese lung cancer (LC) samples.
|
24253382 |
2014 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing an array comparative genomic hybridization analysis to detect copy number changes, we have been the first to identify PPME1 gene amplification in 3.8% (5/131) of Chinese gastric cancer (GC) samples and 3.1% (4/124) of Chinese lung cancer (LC) samples.
|
24253382 |
2014 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing an array comparative genomic hybridization analysis to detect copy number changes, we have been the first to identify PPME1 gene amplification in 3.8% (5/131) of Chinese gastric cancer (GC) samples and 3.1% (4/124) of Chinese lung cancer (LC) samples.
|
24253382 |
2014 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing an array comparative genomic hybridization analysis to detect copy number changes, we have been the first to identify PPME1 gene amplification in 3.8% (5/131) of Chinese gastric cancer (GC) samples and 3.1% (4/124) of Chinese lung cancer (LC) samples.
|
24253382 |
2014 |
|
Endometrial adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here, we report the finding that PME-1 overexpression correlates with increased cell proliferation and invasive phenotypes in endometrial adenocarcinoma cells, where it helps maintain activated ERK and Akt by inhibiting PP2A.
|
24928782 |
2014 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
By performing an array comparative genomic hybridization analysis to detect copy number changes, we have been the first to identify PPME1 gene amplification in 3.8% (5/131) of Chinese gastric cancer (GC) samples and 3.1% (4/124) of Chinese lung cancer (LC) samples.
|
24253382 |
2014 |
|
Astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these observations identify PME-1 expression as one mechanism by which ERK pathway activity is maintained in cancer cells and suggest an important functional role for PME-1 in the disease progression of human astrocytic gliomas.
|
19293187 |
2009 |
|
Malignant Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, PME-1 is shown to support ERK pathway signaling upstream of Raf, but downstream of growth factor receptors and protein kinase C. In malignant gliomas, PME-1 expression levels correlate with both ERK activity and cell proliferation in vivo.
|
19293187 |
2009 |